Trial Profile

A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belcesiran (Primary)
Indications Alpha 1-antitrypsin deficiency
Focus Adverse reactions; First in man
Sponsors Dicerna Pharmaceuticals

Most Recent Events

27 Mar 2024 Status changed from active, no longer recruiting to completed.
14 Nov 2023 Results assessing safety and efficacy of Belcesiran in Healthy Volunteers presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
12 Sep 2022 Planned End Date changed from 1 Jun 2022 to 1 May 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com